Bavarian Nordic-sponsored study has commenced dosing Study marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in s...

Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced top line ...

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an impor...

Study Seeks to Confirm Efficacy and Safety of Next-generation Clot-dissolving Therapy Consisting of Low-dose tPA and HisproUK. Cambridge, Mass., USA, September 05, 20...

Odense, Denmark, September 10, 2018 / B3C newswire / -- RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed second closing of its S...

Clinerion and Semicrol announce a collaboration which will integrate the functionality of Clinerion’s Patient Network Explorer with Semicrol’s Fundanet CTMS. The part...